Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media

被引:7
|
作者
Izurieta, Patricia [1 ]
Scherbakov, Michael [2 ]
Guevara, Javier Nieto [3 ]
Vetter, Volker [1 ]
Soumahoro, Lamine [1 ]
机构
[1] GSK, Ave Fleming 20, B-1300 Wavre, Belgium
[2] GSK, Moscow, Russia
[3] GSK, Panama City, Panama
关键词
effectiveness; impact; incidence; otitis media; pneumococcal conjugate vaccine; systematic literature review; vaccine; NONTYPABLE HAEMOPHILUS-INFLUENZAE; TYMPANOSTOMY TUBE PLACEMENTS; STREPTOCOCCUS-PNEUMONIAE; PROTEIN-D; NASOPHARYNGEAL CARRIAGE; CHILDREN; 10-VALENT; VACCINATION; MICROBIOLOGY; INFECTIONS;
D O I
10.1080/21645515.2021.2013693
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Otitis media (OM) is a common disease of childhood and available pneumococcal conjugate vaccines (PCVs), with different compositions, could have different impact on OM reduction. This systematic literature review evaluated available data describing the efficacy, effectiveness, and impact of 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) and 13-valent PCV (PCV13) on OM outcomes. Statistically significant reductions in all-cause and complicated OM, tympanostomy tube placement and OM-related hospitalizations were consistently observed after the introduction of PHiD-CV and PCV13. Impact studies with data in children <2 years of age using PCV13 report 47-51% and PHiD-CV 34-43% reduction of all-cause OM (primary care, outpatient, ambulatory, emergency department visits) compared to periods before PCV introduction. When the impact of both vaccines is assessed in comparable settings, some studies suggest PHiD-CV may offer better protection against some OM outcomes. Well-designed, head-to-head comparisons are needed to better understand the differences and guide vaccination policies. Plain Language Summary What is the context? Pneumococcal vaccines are highly effective in preventing pneumonia and meningitis in children. The two main Pneumococcal vaccines are PHiD-CV (Synflorix, GSK) and PCV13 (Prevenar 13, Pfizer). Both vaccines have been shown to provide protection against otitis media despite differing in their composition. However, it is currently unknown if both vaccines confer similar level of protection against otitis media. What is new? We conducted a literature review to evaluate the effects of PHiD-CV and PCV13 on the otitis media. From 33 articles, we found that: double dagger Both vaccines were effective in reducing doctor visits for otitis media as well as the number of severe cases and cases requiring hospitalization. double dagger Four studies suggested a higher level of protection provided by PHiD-CV compared to PCV13, although more data is needed to confirm his finding. What is the impact? Available information shows that PHiD-CV and PCV13 are effective in preventing a proportion of otitis media during childhood. Given the remaining substantial burden associated with the disease and the related significant usage of antibiotics, the development of improved vaccines with higher impact on otitis media would be welocme.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE MENINGOCOCCAL OUTER-MEMBRANE PROTEIN COMPLEX CONJUGATE VACCINES - IMMUNOGENICITY AND EFFICACY IN EXPERIMENTAL PNEUMOCOCCAL OTITIS-MEDIA
    GIEBINK, GS
    KOSKELA, M
    VELLA, PP
    HARRIS, M
    LE, CT
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (02): : 347 - 355
  • [42] Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in US Seniors
    Smith, Kenneth J.
    Wateska, Angela R.
    Nowalk, Mary Patricia
    Lin, Chyongchiou J.
    Harrison, Lee H.
    Schaffner, William
    Zimmerman, Richard K.
    [J]. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2021, 61 (01) : 28 - 36
  • [43] A systematic literature review and network meta-analysis feasibility study to assess the comparative efficacy and comparative effectiveness of pneumococcal conjugate vaccines
    McGirr, Ashleigh
    Iqbal, Shehzad M.
    Izurieta, Patricia
    Talarico, Carla
    Luijken, Janneke
    Redig, Josefine
    Newson, Rachel S.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (11) : 2713 - 2724
  • [44] The Clinical Effectiveness of Pneumococcal Conjugate Vaccines A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Ewald, Hannah
    Briel, Matthias
    Vuichard, Danielle
    Kreutle, Veronika
    Zhydkov, Andriy
    Gloy, Viktoria
    [J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2016, 113 (09): : 139 - +
  • [45] Changing Trends of Acute Otitis Media Bacteriology in Central Israel in the Pneumococcal Conjugate Vaccines Era
    Tamir, Sharon Ovnat
    Roth, Yehudah
    Dalal, Ilan
    Goldfarb, Abraham
    Grotto, Itamar
    Marom, Tal
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (02) : 195 - 199
  • [46] Impact of 13-valent pneumococcal conjugate vaccine on otitis media bacteriology
    Zhao, Alice S.
    Boyle, Sean
    Butrymowicz, Anna
    Engle, Robert D.
    Roberts, Jason M.
    Mouzakes, Jason
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2014, 78 (03) : 499 - 503
  • [47] Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006)
    Oosterhuis-Kafeja, Froukje
    Beutels, Philippe
    Van Damme, Pierre
    [J]. VACCINE, 2007, 25 (12) : 2194 - 2212
  • [48] Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland
    Allemann, Aurelie
    Frey, Pascal M.
    Brugger, Silvio D.
    Hilty, Markus
    [J]. VACCINE, 2017, 35 (15) : 1946 - 1953
  • [49] Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom
    Wilson, Michele
    Lucas, Aaron
    Mendes, Diana
    Vyse, Andrew
    Mikudina, Boglarka
    Czudek, Carole
    Ellsbury, Gillian Frances
    Perdrizet, Johnna
    [J]. VACCINES, 2023, 11 (07)
  • [50] Efficacy of pneumococcal conjugate vaccine against PCR-positive acute otitis media
    Palmu, Arto A.
    Saukkoriipi, Annika
    Jokinen, Jukka
    Leinonen, Maija
    Kilpi, Terhi M.
    [J]. VACCINE, 2009, 27 (10) : 1490 - 1491